Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
  • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the invention relates to intermediate acting neuromuscular blocking agents and methods for using and counteracting the effects of such neuromuscular blocking agents.
• NMB neuromuscular blocker
• Curare d- tubocurarine
• Neuromuscular blockers are categorized both by their mechanism of action (nondepolarizing or depolarizing) and by their duration of action (ultra- short, short-, intermediate-, and long-acting).
• the maximum clinical duration of such neuromuscular blocker as defined by the FDA is the time for return to 25% of control in a twitch response test after a dose of twice the 95% effective dose (EDg 5 ).
• This maximum duration time for an ultra-short neuromuscular blocker is 8 minutes, for a short neuromuscular blocker the duration is 20 minutes, for an intermediate neuromuscular blocker the duration time is 50 minutes and the duration time for a long acting neuromuscular blocker is greater than 50 minutes. See Bedford, Anesthesiology 1995, 82, 33 A.
• neuromuscular blocking adjuncts to anesthesia examples include the long- acting agent metocurine (Ib), the ultra-short-acting succinylcholine (2), the short-acting relaxant mivacurium (3), and the long-acting agent doxacurium (4).
• the benzyltetrahydroisoquinoline-based relaxants are nondepolarizing neuromuscular blockers.
• Succinylcholine (2) is a depolarizing agent.
• Depolarizing neuromuscular blockers are nicotinic acetylcholine receptor agonists and produce a number of unwanted side-effects associated with their mechanism of action. Naguib et al., Anesthesiology 2002, 96, 202-231; Mahajan, Curr. Anaesth. Crit. Care 1996, 7, 289-294; Belmont, Curr. Opin. Anesthesiol. 1995, 8, 362-366; Durant et al., Br. J. Anaesth. 1982, 54, 195-208. These untoward effects can, in rare instances, include anaphylaxis, hyperkalemia, malignant hyperthermia, and cardiac arrhythmias. More common side-effects of depolarizing neuromuscular blockers include fasciculations, severe muscle pain, increased intraocular pressure, and increased intragastric tension.
• the invention relates to novel intermediate neuromuscular blocking agents.
• Other aspects of the invention include methods, compositions and kits for controlling the maximum clinical duration of these intermediate neuromuscular blocking agents.
• the methods of the invention involve fast-acting agents that antagonize the neuromuscular blockade caused by administration of the present intermediate neuromuscular blocking agents.
• Agents that can antagonize the neuromuscular blockade caused by administration of the present neuromuscular blocking agents include cysteine, N- acetylcysteine, glutathione, as well as related cysteine analogs and combinations thereof.
• one aspect of the invention is a neuromuscular blocking agent selected from the group consisting of:
• Another aspect of the invention is a therapeutic method of generating a neuromuscular blockade in a mammal comprising administering to the mammal an effective amount of a neuromuscular blocking agent of the invention.
• Another aspect of the invention is a therapeutic method of antagonizing a neuromuscular blockade caused by administration to a mammal of a neuromuscular blocking agent of the invention, wherein the method comprises administering an effective amount of a neuromuscular blockade antagonist to the mammal.
• neuromuscular blockade antagonists examples include cysteine, glutathione, N-acetylcysteine, homocysteine, methionine, S-adenosyl- methionine, penicillamine, a related cysteine analog, a combination thereof or a pharmaceutically acceptable salt thereof.
• the antagonist is cysteine.
• the antagonist is cysteine combined with glutathione.
• the antagonist is cysteine or glutathione combined with any of the other antagonists.
• the combination of cysteine and glutathione is particularly effective.
• the invention further provides a kit that includes, separately packaged, (a) at least one of the present neuromuscular blocking agents in an amount sufficient to relax or block skeletal muscle activity, and (b) an amount of an antagonist to the neuromuscular blocking agent(s) effective to reverse the effects of the blocking agent on a mammal, with (c) instructions explaining how to administer the neuromuscular blocking agent to a mammal and how to employ the antagonist to reverse the effects of the blocking agent on the mammal to which the blocking agent was administered.
• Such an antagonist to a neuromuscular blocking agent can, for example, be cysteine, glutathione, N- acetylcysteine, homocysteine, methionine, S-adenosyl-methionine, penicillamine, a combination thereof or pharmaceutically acceptable salts thereof in combination.
• the antagonist is cysteine.
• the antagonist is cysteine combined with a cysteine analog.
• the combination of cysteine and glutathione is particularly effective.
• FIG. 1 graphically illustrates the duration of neuromuscular blockade in monkeys caused by administration of 0.1 mg/kg AVOOl neuromuscular blocking agent with ( ⁇ ) and without ( ⁇ ) administration of neuromuscular blockade antagonists (a combination of 20 mg/kg cysteine and 10 mg/kg glutathione).
• AVOOl neuromuscular blocking agent
• ⁇ ⁇
• ⁇ ⁇
• neuromuscular blockade antagonists a combination of 20 mg/kg cysteine and 10 mg/kg glutathione
• FIG. 2 graphically illustrates the effects of cysteine plus glutathione administration at different times after administering either 0.1 mg/kg or 3.0 mg/kg AVOOl neuromuscular blocking agent.
• FIG. 3 is a dose-response curve for the AV002 neuromuscular blocking agent plotted using a log scale. As illustrated, the effective dosage for 95% neuromuscular blockade is 0.045 mg/kg and the effective dosage for 50% neuromuscular blockade is 0.031 mg/kg.
• FIG. 4 graphically illustrates the duration of neuromuscular blockade in monkeys caused by administration of 0.1 mg/kg AV002 neuromuscular blocking agent with ( ⁇ ) and without ( ⁇ ) administration of neuromuscular blockade antagonists (a combination of 20 mg/kg cysteine and 10 mg/kg glutathione).
• AV002 neuromuscular blocking agent
• ⁇ ⁇
• ⁇ ⁇
• neuromuscular blockade antagonists a combination of 20 mg/kg cysteine and 10 mg/kg glutathione
• FIG. 5 graphically illustrates the effect of AV002 dosage on the duration of neuromuscular blockade in monkeys after administration of neuromuscular blockade antagonists.
• the AV002 dosage is 0.1 mg/kg (A)
• reversal of the blockade with a combination of 20 mg/kg cysteine and 10 mg/kg glutathione takes a little less than 200 seconds.
• the AV002 dosage is 0.2 mg/kg ( ⁇ )
• reversal of the blockade with a combination of 20 mg/kg cysteine and 10 mg/kg glutathione takes about 500 seconds.
• FIG. 6 graphically illustrates the duration of neuromuscular blockade in monkeys caused by administration of 0.2 mg/kg AV002 neuromuscular blocking agent with ( ⁇ ) and without ( ⁇ ) administration of neuromuscular blockade antagonists (a combination of 20 mg/kg cysteine and 10 mg/kg glutathione).
• AV002 neuromuscular blocking agent
• ⁇ ⁇
• ⁇ ⁇
• neuromuscular blockade antagonists a combination of 20 mg/kg cysteine and 10 mg/kg glutathione
• FIG. 7 graphically summarizes the duration of neuromuscular blockade in monkeys caused by administration of the AVOOl (bars with ⁇ ) and the AV002 (bars with III) neuromuscular blocking agents.
• the bar to the far right without cross-hatching illustrates how administration of an antagonist shortens the duration of the AV002 neuromuscular blockade, where the antagonist used was a combination of cysteine and glutathione.
• FIG. 8 graphically summarizes the mean arterial blood pressure ( ⁇ ), the heart rate ( ⁇ ) and the maximal block ( ⁇ ) observed for increasing dosages of the AV002 neuromuscular blocking agent.
• FIG. 9 graphically summarizes the mean arterial blood pressure ( ⁇ ), the heart rate ( ⁇ ) and the maximal block ( ⁇ ) observed for increasing dosages of the AVOOl neuromuscular blocking agent.
• FIG. 10 is a dose-response curve for the AVOOl neuromuscular blocking agent plotted on a log scale. As illustrated, the effective dosage for 95% neuromuscular blockade is 0.040 mg/kg and the effective dosage for 50% neuromuscular blockade is 0.027 mg/kg.
• FIG. 11 illustrates recovery times from a neuromuscular blockade caused by AV002 (0.15mg/kg) by a variety of reversal agents or without (*) a reversal agent.
• the effect of 30 mg/kg cysteine plus 30 mg/kg glutathione administered at 1 minute ( ⁇ ) after AV002 administration or at the first sign of twitch recovery ( ⁇ ) is fast, as illustrated.
• traditional reversal agents neostigmine (0.05 mg/kg) and atropine (0.03 mg/kg) administered at 1 minute after AV002 administration (A) and at first recovery of twitch (•), are slow, as shown.
• the present invention relates to novel neuromuscular blocking agents of intermediate duration and methods for regulating the duration of these neuromuscular blocking agents.
• Neuromuscular blocking agents can literally paralyze a patient for the time during which they are active.
• the use of neuromuscular blocking agents is restricted to situations where muscle relaxation is essential for effective treatment of a patient, for example, selected surgical procedures and those involving intubation of the trachea. Because paralysis can interfere with essential body functions (e.g. breathing) the physician selects a neuromuscular blocking agent that will be active for as long as needed but no more than is needed.
• a neuromuscular blocking agent is used to relax the tracheal muscles and permit intubation.
• the neuromuscular blocking agent also relaxes the muscles of the chest, thereby causing the patient to stop breathing.
• the anesthesiologist must quickly insert the breathing tube into the patient's trachea and begin ventilation of the lungs. If the tube cannot be inserted quickly enough, the physician must intervene with some form of artificial resuscitation or the patient may suffer oxygen deprivation, and the associated tissue damage from lack of oxygen.
• Fast reversal of the neuromuscular blocking agent by a rapidly acting antagonist can remove the patient from danger and avoid sustained artificial resuscitation.
• the invention provides methods of using these blocking agents and fast, reliable methods for counteracting the effects of these intermediate duration neuromuscular blocking agents so that a patient will recover from the effects of such neuromuscular blocking agents within a few minutes after administering the appropriate antagonist.
• the compounds of the invention are safer and more reliable neuromuscular blocking agents than currently available combinations of neuromuscular agents and antagonists, particularly because the neuromuscular blockade can be counteracted with cysteine and cysteine-like molecules at any time, even just after administration of the blocking agent. This cannot be done with currently available neuromuscular blocking agents and antagonists.
• an anesthesiologist must wait until a patient is spontaneously beginning to recover from currently available neuromuscular blocking agents before administering antagonists that are commonly available at this time. In the case of currently available neuromuscular blocking agents this waiting time may from 30 to 60 minutes or more.
• the reversal agents of the invention effectively remove the neuromuscular blockade caused by the present blocking agents within a few minutes.
• the cysteine and cysteine-like antagonists of the invention also have substantially no side effects.
• the antagonists of the invention are compounds that are naturally found in the body and cause essentially no change in pulse rate, blood pressure or other indicators of cardiac function.
• the cysteine and cysteine-like antagonists of the invention act directly on neuromuscular blocking agents and quickly convert them to inactive chemical derivatives.
• the cysteine and cysteine-like antagonists of the invention do not require inhibition of an important endogenous enzyme system, which is required by currently available antagonists of neuromuscular blocking agents such as neostignine, edrophonium and other cholinesterase inhibitors.
• the neuromuscular blocking agents of the invention have the following structures.
• cysteine, N-acetylcysteine, glutathione, related cysteine analogs and combinations thereof can be used to shorten the duration of the present neuromuscular blocking agents. While the inventor has previously observed that cysteine can reverse the neuromuscular blockade of chlorofumarate neuromuscular blocking agents, the chlorine on these blocking agents was thought to be needed for cysteine reversal. However the present neuromuscular blocking agents have no chlorine or other halide. Thus, it is surprising that cysteine, glutathione and other cysteine-like antagonists can rapidly and fully reverse the neuromuscular blockade caused by administration of the present agents.
• cysteine-like molecules such as cysteine and glutathione have no reversal effect whatsoever on recovery from blockades produced by other benzylisoquinolinium-based neuromuscular blocking drugs such as mivacurium, doxacurium and cisatracurium. Therefore, as illustrated herein, reversal by cysteine-like antagonists is effective when the neuromuscular blocking agent has a fumarate double bond, where activating carboxyl groups are immediately adjacent (i.e., a-) to the double bond.
• mivacurium contains a double bond in the center of the molecule, this bond is separated from the carboxyl groups by two carbon atoms.
• a neuromuscular blockade caused by mivacurium cannot be reversed by a cysteine-like molecule.
• the inventors have found that while blockades caused by chlorofumarates can be reversed by cysteine, other halogenated agents, for example, like those listed by Bigham et al. (U.S. Patent 6,177,445), including fluorofumarates and difluorosuccinates, are unaffected by cysteine/glutathione.
• the compounds listed by Bigham et al are described as ultra- short acting and are all halogenated.
• the compounds of the present invention are particularly unique in that they are not halogenated, are intermediate in duration, and can be rapidly reversed by cysteine/glutathione because of the presence of the fumarate double bond and the activating adjacent carboxyl groups. It is believed that the compounds of the present invention are the only non-chlorinated neuromuscular blocking agents whose effects can be rapidly terminated, at any time, by one of the present antagonists, or a combination thereof.
• the antagonist molecules used in the methods of the invention include any substantially nontoxic compound having a sulfhydryl and/or amino substituent that can reduce the duration of a neuromuscular blockade caused by one of the present neuromuscular blocking agents.
• antagonists include cysteine, N-acetylcysteine, glutathione, homocysteine, methionine, S- adenosyl-methionine, penicillamine and related cysteine analogs.
• One aspect of the invention is a method of inducing paralysis or a neuromuscular blockade in a mammal by administering an effective amount of one of the present neuromuscular blocking agents.
• the present invention also provides a method for reversing the paralysis or the neuromuscular blockade in a mammal that caused by the present neuromuscular blocking agents, by administering to the mammal an amount of a cysteine or cysteine-like molecule that is effective for reversing the neuromuscular block produced by a neuromuscular blocking agent of the invention.
• the effective amount or dosage of the present neuromuscular blocking agents for each subject may vary.
• an effective amount or dosage of the present neuromuscular blocking agent to obtain paralysis in mammals is about 0.01 to 20.0 mg/kg of body weight, or about 0.02 to 2.0 mg/kg of body weight, where this dosage is based on the weight of the di-cation, which is the active ingredient.
• the dosage is about two to eight times that employed for an intravenous dose.
• the intramuscular dosage is about 0.02 to 80.0 mg/kg of body weight, or about 0.04 to 8.0 mg/kg of body weight.
• the present invention also provides the use of cysteine or a cysteine-like molecule with or without a compound of the invention in the manufacture of a medicament for reversing neuromuscular blockade in a mammal, including in a human.
• cysteine, cysteine-like molecules and/or compounds of the invention While it is possible for the cysteine, cysteine-like molecules and/or compounds of the invention to be administered as the bulk active chemicals, it is preferred to present them in the form of a pharmaceutical formulation for parenteral administration. Accordingly, the present invention provides one pharmaceutical formulation which comprises a therapeutically effective amount of a neuromuscular blocking agent of the invention. Moreover, the invention separately provides a therapeutically effective amount of cysteine or cysteine- like molecule, or a combination of cysteine-like molecules, as hereinbefore defined, and a pharmaceutically acceptable carrier.
• the formulation may be an aqueous or non-aqueous solution or mixture of liquids, which may contain bacteriostatic agents, antioxidants, buffers or other pharmaceutically acceptable additives.
• the compounds may be presented as lyophilized solids for reconstitution with water (for injection) or dextrose or saline solutions.
• Such formulations are normally presented in unit dosage forms such as ampoules or disposable injection devices. They may also be presented in multi-dose forms such as a bottle from which the appropriate dose may be withdrawn. All such formulations should be sterile.
• a suitable dose to obtain a neuromuscular blockade for adult humans is about 0.1 mg to about 500 mg, or in some embodiments about 1 mg to about 500 mg, or in other embodiments about 0.5 mg to about 150 mg, or in further embodiments about 3.5 mg to about 50 mg.
• a suitable pharmaceutical parenteral preparation for administration to humans will preferably contain 0.1 to 50 mg/ml of one or more of the present compounds in solution or multiples thereof for multi-dose vials.
• a suitable dose of cysteine or a cysteine-like molecule to reverse a neuromuscular blockade in adult humans (with an average weight of about 150 lbs.
• a suitable pharmaceutical parenteral preparation for administration to humans will preferably contain 0.1 to 2000 mg/ml of cysteine or a cysteine-like molecule, or a combination of cysteine and cysteine-like molecules, in solution or multiples thereof for multi-dose vials.
• Simple formulations of a solution of the present neuromuscular blocking agents, cysteine and/or cysteine-like molecules can be formulated in sterile water or in saline solutions.
• the neuromuscular blocking agent and cysteine/cysteine-like agents are prepared as separate solutions or formulations. These solutions may be prepared by dissolving the compound(s) in pyrogen-free water or saline, with or without a preservative and sterilizing the solution.
• the formulations may be prepared by dissolving the sterile compound in pyrogen-free, sterile water or a sterile physiological saline solution under aseptic conditions. Particularly preferred formulations have a pH of about 2.0 to 5.0.
• the neuromuscular blocking agents, cysteine and/or cysteine-like molecules of the invention may also be administered as a rapid intravenous bolus over about 5 seconds to about 15 seconds or, alternatively, as slower infusions over about 1 to about 2 minutes of a saline solution, e.g., Ringer's solution in drip form.
• a saline solution e.g., Ringer's solution in drip form.
• the compounds may also be administered in other solvents (usually as a mixed solvent with water) such as alcohol, polyethylene glycol and dimethylsulphoxide. They may also be administered intravenously or intramuscularly (as a drip if required), either as a suspension or solution.
• Rhesus monkeys were anesthetized with ketamine (7.5 mg/Kg) given intramuscularly or intravenously. Anesthesia was maintained with a mixture of isoflurane (1.5 %), nitrous oxide (60%) and oxygen (40%). The common peroneal nerve was stimulated supramaximally with square wave pulses of 0.2 m sec duration at a rate of 0.15 Hz. Twitch contractions were recorded via the tendon of the extensor digitorum muscle.
• trachea was intubated and ventilation was controlled at 12-15 ml/kg, 18-24 breaths per minute.
• a peripheral vein and artery were cannulated for drug administration and for recording of arterial pressure, respectively, hi preliminary studies a neuromuscular blocking agent having one of the following structures was administered intravenously.
• cysteine and/or glutathione was administered to test animals at selected dosages.
• the AVOOl and AV002 blocking agents have an effective dose that achieves 95% neuromuscular blockage (ED95) of 0.04 mg/kg, whereas AV003, which is the corresponding cis isomer of AV002, has an ED95 of 0.20 mg/kg.
• AV003 which is the corresponding cis isomer of AV002
• AV003 A comparison of the trans isomer (AV002) with the cis isomer (AV003) shows that the trans isomer (AV002) is five times more potent.
• the trans isomer (AV002) in this series exhibits greater potency and yet has a shorter duration of action (Table 1).
• the structures of these neuromuscular blocking agents are similar, the duration of the blockade caused by these agents differs (Table 1).
• the duration of a blockade caused by a 4xED95 dosage of AVOOl lasts 50-60 minutes, whereas the blockade caused by a similar dosage of AV002 lasts only 30-35 minutes.
• the AV003 blocking agent causes paralysis for about 45-60 minutes when administered at a 4xED95 dosage.
• Rhesus monkeys were anesthetized and treated with a neuromuscular blocking agent as described in Example 1.
• FIG. 1 shows how quickly, on average, the five Rhesus monkeys tested (Renoir, Morgan, Soutine, Seurat and Winslow) recovered from administration of the neuromuscular blocking agent AVOOl, both spontaneously and when a combination of cysteine (20 mg/kg) and glutathione (10 mg/kg) was administered. Spontaneous recovery from AVOOl administration took about 2800 seconds (about 46.7 minutes, FIG. 1). However, when a combination of cysteine (20 mg/kg) and glutathione (10 mg/kg) was administered at 2 minutes after AVOOl administration, the blockade caused by AVOOl was alleviated much faster - in only about 354 seconds (not quite 6 minutes).
• FIG. 2 shows that the combination of cysteine (20 mg/kg) and glutathione (10 mg/kg) can reverse the effects of a substantial over-dose (30 x the effective dose typically used) of AVOOl.
• a normal dosage 0.1 mg/kg
• a massive overdose 3.0 mg/kg
• a dose response curve for AVOOl is provided as FIG. 10, illustrating that the effective dose to achieve 95% paralysis for AVOOl is 0.040 mg/kg and the effective dose to achieve 50% paralysis is 0.027 mg/kg.
• FIG. 3 shows a dose response curve for the AV002 neuromuscular blocking agent, demonstrating that fairly small increases in dosage can substantially increase the percent neuromuscular blockade.
• the effective dose of AV002 to achieve 95% paralysis is 0.045 mg/kg, while the effective AV002 dose to achieve 50% paralysis is 0.031 mg/kg.
• FIG. 4 illustrates how quickly Rhesus monkeys recovered from administration of 0.1 mg/kg of the AV002 neuromuscular blocking agent, both spontaneously, and when a combination of cysteine (20 mg/kg) and glutathione (10 mg/kg) was administered. Spontaneous recovery from AV002 administration took about 1600 seconds (about 26.7 minutes, FIG. 4). However, when a combination of cysteine (20 mg/kg) and glutathione (10 mg/kg) was administered at 2 minutes after AV002 administration, the blockade caused by AV002 was alleviated much faster - in only about 200 seconds (about 3.3 minutes). Therefore, the combination of cysteine and glutathione was a highly effective composition for reversing the effects of the AV002 neuromuscular blocking agent.
• modulation of the dosage of AV002 can be used to modulate the duration of an AV002-induced neuromuscular blockade.
• use of a combination of cysteine and glutathione quickly reversed the effects of the AV002 blockade.
• increasing the dosage of AV002 from 0.1 mg/kg to 0.2 mg/kg increased the time for reversal of the neuromuscular blockade from about 320 seconds to about 670 seconds. None-the-less, the 670 second reversal time for a higher dosage of AV002 substantially reduced the time for recovery from about 2150 seconds to about 670 seconds.
• the combination of cysteine and glutathione is a highly effective neuromuscular blockade reversal composition.
• FIG. 7 graphically summarizes and compares the duration of AVOOl and AV002 blocking agents.
• FIGs. 8 and 9 provide mean values for the cardiovascular effects of administration of the AV002 and AVOOl neuromuscular blocking agents, respectively as a function of dosage.
• FIG. 8 graphically illustrates that little or no change occurs in the mean arterial pressure ( ⁇ ) and heart rate (A) of animals receiving even high dosages of AV002.
• FIG. 9 graphically illustrates that little or no change occurs in the mean arterial pressure (A) and heart rate ( ⁇ ) of animals receiving high dosages of AV002.
• the AVOOl andAV002 neuromuscular blocking agents exhibit no signs of causing physiological distress to the circulation in vivo.
• This Example illustrates the spontaneous recovery from treatment with AV002 as compared to recovery from AV002 treatment accelerated by cysteine and glutathione.
• the Example illustrates recovery from AV002 treatment using the conventional reversal agents, neostigmine and atropine.
• Anesthesia was induced in adult male rhesus monkeys using 7.5 mg/kg ketamine. Tracheae were intubated using topical anesthetic. Anesthesia was maintained with isoflurane 1-2% and N 2 CVO 2 (60%/40%). ECG, temperature, O 2 saturation, and blood pressure were monitored and maintained within normal limits. Mechanomyogram (MMG) recordings were made of twitch responses from the extensor digitorum at 0.15 Hz. A control dose of AV002 (0.15 mg/kg; about 3 times the ED 95 ) was given and animals were allowed to recover spontaneously. Another dose of 0.15 mg/kg of AV002 was given approximately 30 minutes after return of train of four (TOF) to greater than 100%. Reversal of the second dose of AV002 was attempted in four separate groups of animals with either:
• a dosage of AV002 equivalent to approximately three times the ED95 dosage was most effectively reversed when a combination of cysteine and glutathione was used.
• Table 2 Comparison of Reversal Agents
• AV002 is an intermediate-acting nondepolarizing neuromuscular blocker. Exogenous cysteine and glutathione will reverse neuromuscular block in approximately 3 minutes, even when a dosage of three times the ED 95 dose of AV002 is administered. The 3 minute recovery period was observed when the cysteine and glutathione were given 1 minute following drug injection and at the first sign of twitch recovery. By comparison, traditional reversal with neostigmine was achieved in approximately 10 minutes when neostigmine is given at the first sign of twitch recovery and has no effect on the duration when given one minute after AV002 injection.
• AV002 is a useful neuromuscular blocker that may be used in clinical practice.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=39492558

Family Applications (1)

Country Status (8)

Cited By (3)

Families Citing this family (15)

Citations (4)

Family Cites Families (35)

• 2007
  • 2007-12-05 CA CA2671904A patent/CA2671904C/en active Active
  • 2007-12-05 AU AU2007328210A patent/AU2007328210B2/en active Active
  • 2007-12-05 CN CN2007800505324A patent/CN101588803B/zh active Active
  • 2007-12-05 EP EP07862551A patent/EP2101772B1/en active Active
  • 2007-12-05 US US11/951,114 patent/US8148398B2/en active Active
  • 2007-12-05 WO PCT/US2007/024914 patent/WO2008070121A1/en not_active Ceased
  • 2007-12-05 JP JP2009540280A patent/JP5213137B2/ja active Active
  • 2007-12-05 AT AT07862551T patent/ATE554769T1/de active

Patent Citations (5)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events